Inactive Instrument

Highlights NeuroVive Pharmaceutical AB Swiss Exchange

Equities

NVP

SE0002575340

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	05-30	MT
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	05-30	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-23	CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	12-20	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	11-14	CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	23-10-11	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Abliva AB Announces First Patient Dosed in the Falcon Study	23-06-28	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-24	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333	22-12-06	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-31	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-22	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI
US Food and Drug Administration Approves Abliva's Investigational New Drug Application for KL1333	21-11-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuroVive Pharmaceutical AB Swiss Exchange

Equities

NVP

SE0002575340

Highlights

Filters